source: British Journal of Haematology

year: 2019

authors: Zhou J, Han J, Nutescu EA, Galanter WL, Walton SM, Gordeuk VR, Saraf SL, Calip GS

Conflicting evidence exists on the epidemiology of type 2 diabetes mellitus (T2DM) among patients with sickle cell disease (SCD). This study measured the prevalence, incidence and clinical outcomes associated with T2DM in a large US population of commercially-insured adults aged >=20 years with SCD between 2009 and 2014. Among 7070 patients with SCD, the mean age (median) was 39 (37) years and 60•8% were female. The standardized prevalence of T2DM among patients with SCD showed a modest increase, from 15•7% to 16•5% (P trend = 0•026), and was comparable to African-American respondents to the National Health and Nutrition Examination Survey (18•2%). Over 17 024 person-years, the crude incidence rate for T2DM was 25•4 per 1000 person-years. Incident T2DM was associated with comorbid hypertension (hazard ratio [HR] = 1•45, 95% confidence interval [CI] 1•14-1•83), and dyslipidaemia (HR = 1•43, 95%CI 1•04-1•96). Compared to SCD patients without T2DM, more SCD patients with T2DM had diagnoses of nephropathy (28•0% vs. 9•5%; P < 0•001), neuropathy (17•7% vs. 5•2%; P < 0•001) and stroke (24•1% vs. 9•2%; P < 0•001). Prevalence of T2DM in SCD patients is similar to the general African American population with an increasing trend in recent years. These trends support routine screening for T2DM in aging patients with SCD, especially those with comorbid hypertension and/or dyslipidaemia.

Share

Discuss in Social Wall

Twitter

Share to SCDteam

+myBinder